Related coverage linked through entity extraction aliases.
May 05, 2026
Amylyx is approaching key catalysts ahead of its May 7 earnings report, led by Phase 3 LUCIDITY data for avexitide in post-bariatric hypoglycemia due in the third quarter. The company is also expected to provide updates on AMX0035 in Wolfram syndrome and AMX0114 biomarker data in ALS.
Apr 24, 2026
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
Apr 11, 2026
An experimental ovarian cancer drug, elenagen, more than doubled median survival in a 30-patient mid-stage trial in Belarus. The drug was added to gemcitabine and reduced mortality risk by nearly 60%.
Mar 30, 2026
The artificial intelligence in drug discovery market is projected to grow from USD 3.25 billion in 2026 to USD 10.29 billion by 2031, representing a 25.94% CAGR. AI technologies are accelerating drug discovery timelines, reducing costs, and improving success rates through advanced analytics and machine learning. North America leads market adoption while Asia-Pacific emerges as a high-growth region driven by expanding biotechnology sectors.
Mar 24, 2026
Precision medicine is transforming healthcare through genetic testing and AI integration, with research showing direct-to-consumer testing identifies unknown health risks and drives medical action. However, reimbursement systems lag behind scientific advances, creating barriers to widespread adoption of personalized treatment approaches.
Feb 19, 2026
The FDA will host Rare Disease Day 2026 on February 23, focusing on patient engagement and accelerating treatment development. The agency released its 2026 Strategic Agenda for the Rare Disease Hub, outlining new regulatory pathways and coordination efforts.
